| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Health Plan of Nevada offers you an extended network of providers to choose from, ranging from Primary Care to Specialties. For a complete listing, refer to the Provider Directory link to the right.
CareBridge offers a patented EVV solution for personal care services, home health services, and health plan care managers. Originally launched in 2009, CareBridge has spent more than a decade refining our technology through multiple statewide rollouts.
PaxeraMed Corp. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.